MicroRNAs as potential biomarkers in cancer: Opportunities and challenges

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lan, Huiyin ^a   Lu, Haiqi ^b   Wang, Xian ^b   Jin, Hongchuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; RNA; TUMOR MARKER;

BIOGENESIS; BODY FLUID; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; EXOSOME; GENE EXPRESSION; HUMAN; NEOPLASM; NONHUMAN; PLASMA; PREDICTIVE VALUE; REVIEW; SERUM; TREATMENT RESPONSE; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MICRORNAS; NEOPLASMS; RNA, NEOPLASM;

EID: 84926675821     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/125094     Document Type: Review

References (189)

1. A. J. Atkinson, W. A. Colburn, V. G. DeGruttola et al., "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, " Clinical Pharmacology and Therapeutics, vol. 69, no. 3, pp. 89-95, 2001.
2. R. Lozano, M. Naghavi, K. Foreman et al., "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, " The Lancet, vol. 380, no. 9859, pp. 2095-2128, 2012.
3. V. A. Moyer, "Screening for prostate cancer: U. S. preventive services task force recommendation statement, " Annals of Internal Medicine, vol. 157, no. 2, pp. 120-134, 2012.
4. R. C. Lee, R. L. Feinbaum, and V. Ambros, "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, " Cell, vol. 75, no. 5, pp. 843-854, 1993.
5. Y. W. Kong, D. Ferland-McCollough, T. J. Jackson, and M. Bushell, "microRNAs in cancer management, " The Lancet Oncology, vol. 13, no. 6, pp. e249-e258, 2012.
6. T. A. Farazi, H. M. Horlings, J. J. Ten Hoeve et al., "MicroRNA sequence and expression analysis in breast tumors by deep sequencing, " Cancer Research, vol. 71, no. 13, pp. 4443-4453, 2011.
7. C. Wilson, S. Schulz, and S. A. Waldman, "Biomarker development, commercialization, and regulation: individualization of medicine lost in translation, " Clinical pharmacology and therapeutics, vol. 81, no. 2, pp. 153-155, 2007.
8. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function, " Cell, vol. 116, no. 2, pp. 281-297, 2004.
9. J. Krol, I. Loedige, and W. Filipowicz, "The widespread regulation of microRNA biogenesis, function and decay, " Nature Reviews Genetics, vol. 11, no. 9, pp. 597-610, 2010.
10. V. N. Kim, J. Han, and M. C. Siomi, "Biogenesis of small RNAs in animals, " Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 126-139, 2009.
11. C. P. Concepcion, C. Bonetti, and A. Ventura, "TheMicroRNA-17-92 family ofMicroRNAclusters indevelopment anddisease, " Cancer Journal, vol. 18, no. 3, pp. 262-267, 2012.
12. X. Cai, C. H. Hagedorn, and B. R. Cullen, "Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs, " RNA, vol. 10, no. 12, pp. 1957-1966, 2004.
13. Y. Lee, C. Ahn, J. Han et al., "The nuclear RNase III Drosha initiates microRNA processing, " Nature, vol. 425, no. 6956, pp. 415-419, 2003.
14. M. D. Jansson and A. H. Lund, "MicroRNA and cancer, " Molecular Oncology, vol. 6, no. 6, pp. 590-610, 2012.
15. R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel, "Most mammalian mRNAs are conserved targets of microRNAs, " Genome Research, vol. 19, no. 1, pp. 92-105, 2009.
16. X.-Y. Li, Q.-F. Luo, C.-K. Wei, D.-F. Li, J. Li, and L. Fang, "MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer, " International Journal of Clinical and Experimental Medicine, vol. 7, no. 1, pp. 32-40, 2014.
17. B. Wojtas, C. Ferraz, T. Stokowy et al., "Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas, "Molecular and Cellular Endocrinology, vol. 388, no. 1-2, pp. 1-9, 2014.
18. C. Furdui, "Ionizing radiation: mechanisms and therapeutics, " Antioxidants & Redox Signaling, vol. 21, no. 2, pp. 218-220, 2014.
19. I. Koturbash, F. J. Zemp, I. Pogribny, and O. Kovalchuk, "Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis, " Mutation Research, vol. 722, no. 2, pp. 94-105, 2011.
20. G. A. Calin, C. D. Dumitru, M. Shimizu et al., "Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15524-15529, 2002.
21. G. Di Leva, M. Garofalo, and C. M. Croce, "MicroRNAs in cancer, " Annual Review of Pathology, vol. 9, pp. 287-314, 2014.
22. E. Rao, C. Jiang, M. Ji et al., "The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth inmantle cell lymphoma via PI3K/AKT pathway activation, " Leukemia, vol. 26, no. 5, pp. 1064-1072, 2012.
23. N. H. Kim, H. S. Kim, N. G. Kim et al., "p53 and microRNA-34 are suppressors of canonical Wnt signaling, " Science Signaling, vol. 4, no. 197, article ra71, 2011.
24. N. H. Kim, H. S. Kim, X.-Y. Li et al., "A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition, " The Journal of Cell Biology, vol. 195, no. 3, pp. 417-433, 2011.
25. S. M. Johnson, H. Grosshans, J. Shingara et al., "RAS is regulated by the let-7 microRNA family, " Cell, vol. 120, no. 5, pp. 635-647, 2005.
26. K. Mazan-Mamczarz and R. B. Gartenhaus, "Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), " Leukemia Research, vol. 37, no. 11, pp. 1420-1428, 2013.
27. M. Ouyang, Y. Li, S. Ye et al., "MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer, " PLoS ONE, vol. 9, no. 5, Article ID e96228, 2014.
28. Y. Dong, W. K. K. Wu, C. W. Wu, J. J. Y. Sung, J. Yu, and S. S. M. Ng, "MicroRNAdysregulation in colorectal cancer: a clinical perspective, " British Journal of Cancer, vol. 104, no. 6, pp. 893-898, 2011.
29. M. Maugeri-Sacca, V. Coppola, D. Bonci, and R. De Maria, "MicroRNAs and prostate cancer: from preclinical research to translational oncology, " Cancer Journal, vol. 18, no. 3, pp. 253-261, 2012.
30. C. A. Tumilson, R. W. Lea, J. E. Alder, and L. Shaw, "Circulating microRNA biomarkers for glioma and predicting response to therapy, " Molecular Neurobiology, 2014.
31. G. A. Calin and C. M. Croce, "MicroRNA signatures in human cancers, " Nature Reviews Cancer, vol. 6, no. 11, pp. 857-866, 2006.
32. A. J. Schetter, S. Y. Leung, J. J. Sohnet al., "MicroRNAexpression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, " The Journal of the American Medical Association, vol. 299, no. 4, pp. 425-436, 2008.
33. N. Yanaihara, N. Caplen, E. Bowman et al., "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, " Cancer Cell, vol. 9, no. 3, pp. 189-198, 2006.
34. M. A. Ko, G. Zehong, C. Virtanen et al., "MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy, " Annals of Thoracic Surgery, vol. 94, no. 4, pp. 1094-1103, 2012.
35. S. R. Baglio, V. Devescovi, D. Granchi, and N. Baldini, "Micro-RNA expression profiling of human bone marrow mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31, " Gene, vol. 527, no. 1, pp. 321-331, 2013.
36. M. Ferracin, M. Pedriali, A. Veronese et al., "MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin, " Journal of Pathology, vol. 225, no. 1, pp. 43-53, 2011.
37. Y. M. Youssef, N. M. A. White, J. Grigull et al., "Accuratemolecular classification of kidney cancer subtypes using MicroRNA signature, " European Urology, vol. 59, no. 5, pp. 721-730, 2011.
38. S. Gilad, G. Lithwick-Yanai, I. Barshack et al., "Classification of the four main types of lung cancer using a microRNA-based diagnostic assay, " The Journal of Molecular Diagnostics, vol. 14, no. 5, pp. 510-517, 2012.
39. M. C. Du Rieu, J. Torrisani, J. Selves et al., "MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions, " Clinical Chemistry, vol. 56, no. 4, pp. 603-612, 2010.
40. G. A. Calin, M. Ferracin, A. Cimmino et al., "A microRNA signature associatedwith prognosis and progression in chronic lymphocytic leukemia, " The New England Journal of Medicine, vol. 353, no. 17, pp. 1793-1801, 2005.
41. A. Markou, Y. Liang, and E. Lianidou, "Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer, " Clinical Chemistry and LaboratoryMedicine, vol. 49, no. 10, pp. 1591-1603, 2011.
42. W. Zhu, X. Liu, J. He, D. Chen, Y. Hunag, and Y. K. Zhang, "Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study, " BMC Cancer, vol. 11, article 393, 2011.
43. W. Chen, F. Cai, B. Zhang, Z. Barekati, and X. Y. Zhong, "The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers, " Tumor Biology, vol. 34, no. 1, pp. 455-462, 2013.
44. F. Rothe, M. Ignatiadis, C. Chaboteaux et al., "GlobalmicroRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer, " PLoS ONE, vol. 6, no. 6, Article ID e20980, 2011.
45. J. C. Brase, M. Johannes, T. Schlomm et al., "Circulating miRNAs are correlated with tumor progression in prostate cancer, " International Journal of Cancer, vol. 128, no. 3, pp. 608-616, 2011.
46. K. K. Shih, L.-X. Qin, E. J. Tanner et al., "A microRNA survival signature (MiSS) for advanced ovarian cancer, " Gynecologic Oncology, vol. 121, no. 3, pp. 444-450, 2011.
47. X. Li, Y. Zhang, Y. Zhang, J. Ding, K. Wu, andD. Fan, "Survival prediction of gastric cancer by a seven-microRNA signature, " Gut, vol. 59, no. 5, pp. 579-585, 2010.
48. J. X. Zhang, W. Song, Z. H. Chen et al., "Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis, " The Lancet Oncology, vol. 14, no. 13, pp. 1295-1306, 2013.
49. L. Lei, Y. Huang, andW. Gong, "miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN, " Oncology Reports, vol. 30, no. 6, pp. 2897-2902, 2013.
50. M. Xu, H. Jin, C. X. Xu, W. Z. Bi, andY. Wang, "MiR-34c inhibits osteosarcoma metastasis and chemoresistance, " Medical Oncology, vol. 31, no. 6, p. 972, 2014.
51. F. Meng, R. Henson, M. Lang et al., "Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines, " Gastroenterology, vol. 130, no. 7, pp. 2113-2129, 2006.
52. E. Giovannetti, N. Funel, G. J. Peters et al., "MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity, " Cancer Research, vol. 70, no. 11, pp. 4528-4538, 2010.
53. M. Zhou, Z. Liu, Y. Zhao et al., "MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression, " The Journal of Biological Chemistry, vol. 285, no. 28, pp. 21496-21507, 2010.
54. N. Mosakhani, V. K. Sarhadi, I. Borze et al., "MicroRNA profiling differentiates colorectal cancer according to KRAS status, " Genes Chromosomes and Cancer, vol. 51, no. 1, pp. 1-9, 2012.
55. G. Nakajima, K. Hayashi, Y. Xi et al., "Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer, " Cancer Genomics and Proteomics, vol. 3, no. 5, pp. 317-324, 2006.
56. G. J. Weiss, L. T. Bemis, E. Nakajima et al., "EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines, " Annals of Oncology, vol. 19, no. 6, pp. 1053-1059, 2008.
57. C. P. Carden, D. Sarker, S. Postel-Vinay et al., "Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?" Drug Discovery Today, vol. 15, no. 3-4, pp. 88-97, 2010.
58. Y. Xi, G. Nakajima, E. Gavin et al., "Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples, " RNA, vol. 13, no. 10, pp. 1668-1674, 2007.
59. K. R. M. Leite, J. M. S. Canavez, S. T. Reis et al., "miRNAanalysis of prostate cancer by quantitative real time PCR: comparison between formalin-fixed paraffin embedded and fresh-frozen tissue, " Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 5, pp. 533-537, 2011.
60. X. Chen, Y. Ba, L. Ma et al., "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, " Cell Research, vol. 18, no. 10, pp. 997-1006, 2008.
61. L. Cheng, R. A. Sharples, B. J. Scicluna, and A. F. Hill, "Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood, " Journal of Extracellular Vesicles, vol. 3, 2014.
62. V. Muralidharan-Chari, J. W. Clancy, A. Sedgwick, and C. DSouza-Schorey, "Microvesicles: mediators of extracellular communication during cancer progression, " Journal of Cell Science, vol. 123, no. 10, pp. 1603-1611, 2010.
63. A. Zernecke, K. Bidzhekov, H. Noels et al., "Delivery of micro-RNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection, " Science Signaling, vol. 2, no. 100, p. ra81, 2009.
64. A. Turchinovich, L. Weiz, A. Langheinz, and B. Burwinkel, "Characterization of extracellular circulating microRNA, " Nucleic Acids Research, vol. 39, no. 16, pp. 7223-7233, 2011.
65. L. S. Lee, A. E. Szafranska-Schwarzbach, D. Wylie et al., "Investigating MicroRNA expression profiles in pancreatic cystic neoplasms, " Clinical and Translational Gastroenterology, vol. 5, article e47, 2014.
66. I. Casanova-Salas, J. Rubio-Briones, A. Calatrava et al., "Identification of miR-187 and miR-182 as Biomarkers of EarlyDiagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy, " Journal of Urology, 2014.
67. J. A. Weber, D. H. Baxter, S. Zhang et al., "The microRNA spectrum in 12 body fluids, " Clinical Chemistry, vol. 56, no. 11, pp. 1733-1741, 2010.
68. E. K. O. Ng, W. W. S. Chong, H. Jinet al., "Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening, " Gut, vol. 58, no. 10, pp. 1375-1381, 2009.
69. J. Skog, T. Wurdinger, S. van Rijn et al., "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, " Nature Cell Biology, vol. 10, no. 12, pp. 1470-1476, 2008.
70. M. Fabbri, "TLRs as miRNA receptors, " Cancer Research, vol. 72, no. 24, pp. 6333-6337, 2012.
71. L. Pigati, S. C. Yaddanapudi, R. Iyengar et al., "Selective release of microRNA species from normal and malignant mammary epithelial cells, " PLoS ONE, vol. 5, no. 10, Article IDe13515, 2010.
72. J. Palma, S. C. Yaddanapudi, L. Pigati et al., "MicroRNAs are exported from malignant cells in customized particles, " Nucleic Acids Research, vol. 40, no. 18, pp. 9125-9138, 2012.
73. C. H. Lawrie, S. Gal, H. M. Dunlop et al., "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, " The British Journal of Haematology, vol. 141, no. 5, pp. 672-675, 2008.
74. X. Chen, Z. Hu, W. Wang et al., "Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis, " International Journal of Cancer, vol. 130, no. 7, pp. 1620-1628, 2012.
75. Y. Wang, J. Gu, J. A. Roth et al., "Pathway-based serum micro-RNAprofiling and survival in patients with advanced stage nonsmall cell lung cancer, " Cancer Research, vol. 73, no. 15, pp. 4801-4809, 2013.
76. J. Gong, N. Shen, H. M. Zhang et al., "Agenetic variant in micro-RNA target site of TGF- signaling pathway increases the risk of colorectal cancer in a Chinese population, " Tumor Biology, vol. 35, no. 5, pp. 4301-4306, 2014.
77. G. Genovese, A. Ergun, S. A. Shukla et al., "microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF- signaling in glioblastoma, " Cancer Discovery, vol. 2, no. 8, pp. 736-749, 2012.
78. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating microRNAs as stable blood-based markers for cancer detection, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513-10518, 2008.
79. D. Tang, Y. Shen, M. Wang et al., "Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer, " European Journal of Cancer Prevention, vol. 22, no. 6, pp. 540-548, 2013.
80. K. Cuk, M. Zucknick, J. Heil et al., "Circulating microRNAs in plasma as early detection markers for breast cancer, " International Journal of Cancer, vol. 132, no. 7, pp. 1602-1612, 2013.
81. H. Cai, Y. Yuan, Y.-F. Hao, T.-K. Guo, X. Wei, and Y.-M. Zhang, "Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer, " Medical Oncology, vol. 30, article 452, no. 1, 2013.
82. J. Liu, J. Gao, Y. Du et al., "Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer, " International Journal of Cancer, vol. 131, no. 3, pp. 683-691, 2012.
83. G. van Niel, I. Porto-Carreiro, S. Simoes, and G. Raposo, "Exosomes: a common pathway for a specialized function, " Journal of Biochemistry, vol. 140, no. 1, pp. 13-21, 2006.
84. D. D. Taylor and C. Gercel-Taylor, "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, " Gynecologic Oncology, vol. 110, no. 1, pp. 13-21, 2008.
85. R. J. Bryant, T. Pawlowski, J. W. F. Catto et al., "Changes in circulating microRNA levels associated with prostate cancer, " British Journal of Cancer, vol. 106, no. 4, pp. 768-774, 2012.
86. Y. Ge, L. Xiao, X. Chen, Y. Peng, L. Sun, and F. Liu, "MicroRNAs in peritoneal dialysis effluent are promising biomarkers for peritoneal fibrosis in peritoneal dialysis patients, " Medical Hypotheses, vol. 78, no. 1, pp. 155-156, 2012.
87. N. J. Park, H. Zhou, D. Elashoff et al., "Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection, " Clinical Cancer Research, vol. 15, no. 17, pp. 5473-5477, 2009.
88. M. Hanke, K. Hoefig, H. Merz et al., "A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer, " Urologic Oncology, vol. 28, no. 6, pp. 655-661, 2010.
89. L. Mengual, J. J. Lozano, M. Ingelmo-Torres, C. Gazquez, M. J. Ribal, and A. Alcaraz, "Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer, " International Journal of Cancer, vol. 133, no. 11, pp. 2631-2641, 2013.
90. L. Xing, N. W. Todd, L. Yu, H. Fang, and F. Jiang, "Early detection of squamous cell lung cancer in sputum by a panel of microRNAmarkers, " Modern Pathology, vol. 23, no. 8, pp. 1157-1164, 2010.
91. S. M. Kim, H. W. Kang, W. T. Kim et al., "Cell-free microRNA-from urine as a biomarker for non-muscle-invasive bladder cancer, " Korean Journal of Urology, vol. 54, no. 11, pp. 791-796, 2013.
92. X.-G. Liu, W.-Y. Zhu, Y.-Y. Huang et al., "High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer, " Medical Oncology, vol. 29, no. 2, pp. 618-626, 2012.
93. H.-B. Le, W.-Y. Zhu, D.-D. Chen et al., "Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and post-operative lung carcinoma patients, " Medical Oncology, vol. 29, no. 5, pp. 3190-3197, 2012.
94. G.-H. Liu, Z.-G. Zhou, R. Chen et al., "Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer, " Tumor Biology, vol. 34, no. 4, pp. 2175-2181, 2013.
95. Y. Toiyama, M. Takahashi, K. Hur et al., "Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer, " Journal of the National Cancer Institute, vol. 105, no. 12, pp. 849-859, 2013.
96. E.-H. Cai, Y.-X. Gao, Z.-Z. Wei, W.-Y. Chen, P. Yu, and K. Li, "Serum miR-21 expression in human esophageal squamous cell carcinomas, " Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1563-1567, 2012.
97. P. Wang, L. Zhuang, J. Zhang et al., "The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL, "MolecularOncology, vol. 7, no. 3, pp. 334-345, 2013.
98. W. Ge, D.-C. Yu, Q.-G. Li, X. Chen, C.-Y. Zhang, andY.-T. Ding, "Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances, " Clinical Laboratory, vol. 60, no. 3, pp. 427-434, 2014.
99. Y.-Z. Xu, Q.-H. Xi, W.-L. Ge, and X.-Q. Zhang, "Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 2, pp. 1057-1060, 2013.
100. C.-G. Liu, G. A. Calin, B. Meloon et al., "An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9740-9744, 2004.
101. M. De Planell-Saguer and M. C. Rodicio, "Detection methods for microRNAs in clinic practice, " Clinical Biochemistry, vol. 46, no. 10-11, pp. 869-878, 2013.
102. P. Mestdagh, T. Feys, N. Bernard et al., "High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA, " Nucleic Acids Research, vol. 36, no. 21, article e143, 2008.
103. T. D. Schmittgen, E. J. Lee, J. Jiang et al., "Real-time PCR quantification of precursor and mature microRNA, " Methods, vol. 44, no. 1, pp. 31-38, 2008.
104. J. Shen, S. A. Stass, and F. Jiang, "MicroRNAs as potential biomarkers in human solid tumors, " Cancer Letters, vol. 329, no. 2, pp. 125-136, 2013.
105. J. R. Dijkstra, L. J. M. Mekenkamp, S. Teerenstra, I. de Krijger, and I. D. Nagtegaal, "MicroRNA expression in formalin-fixed paraffin embedded: tissue using real time quantitative PCR: the strengths and pitfalls, " Journal of Cellular and Molecular Medicine, vol. 16, no. 4, pp. 683-690, 2012.
106. W. Li and K. Ruan, "MicroRNA detection by microarray, " Analytical and Bioanalytical Chemistry, vol. 394, no. 4, pp. 1117-1124, 2009.
107. C. J. Creighton, J. G. Reid, and P. H. Gunaratne, "Expression profiling of microRNAs by deep sequencing, " Briefings in Bioinformatics, vol. 10, no. 5, pp. 490-497, 2009.
108. Y. Li, Z. Zhang, F. Liu, W. Vongsangnak, Q. Jing, and B. Shen, "Performance comparison and evaluation of software tools for microRNA deep-sequencing data analysis, " Nucleic Acids Research, vol. 40, no. 10, pp. 4298-4305, 2012.
109. L. Weng, X. Wu, H. Gao et al., "MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffinembedded tissue specimens, " Journal of Pathology, vol. 222, no. 1, pp. 41-51, 2010.
110. M. Wanunu, T. Dadosh, V. Ray, J. Jin, L. McReynolds, and M. Drndic, "Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors, " Nature Nanotechnology, vol. 5, no. 11, pp. 807-814, 2010.
111. Y. Wang, D. Zheng, Q. Tan, M. X. Wang, and L. Q. Gu, "Nanopore-based detection of circulating microRNAs in lung cancer patients, " Nature Nanotechnology, vol. 6, no. 10, pp. 668-674, 2010.
112. D. Madhavan, M. Zucknick, M. Wallwiener et al., "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers inmetastatic breast cancer, " Clinical Cancer Research, vol. 18, no. 21, pp. 5972-5982, 2012.
113. F. Mar-Aguilar, J. A. Mendoza-Ramirez, I. Malagon-Santiago et al., "Serum circulating microRNA profiling for identification of potential breast cancer biomarkers, " Disease Markers, vol. 34, no. 3, pp. 163-169, 2013.
114. X. Luo, C. Stock, B. Burwinkel, and H. Brenner, "Identification and evaluation of plasma microRNAs for early detection of colorectal cancer, " PLoS ONE, vol. 8, no. 5, Article ID e62880, 2013.
115. A. Navarro, T. Diaz, E. Gallardo et al., "Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer, " Journal of Surgical Oncology, vol. 103, no. 5, pp. 411-415, 2011.
116. M. Boeri, C. Verri, D. Conte et al., "MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3713-3718, 2011.
117. Y. Ladeiro, G. Couchy, C. Balabaud et al., "MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations, " Hepatology, vol. 47, no. 6, pp. 1955-1963, 2008.
118. J. F. Ji and X. W. Wang, "New kids on the block diagnostic and prognostic microRNAs in hepatocellular carcinoma, " Cancer Biology andTherapy, vol. 8, no. 18, pp. 1683-1690, 2009.
119. A. Karakatsanis, I. Papaconstantinou, M. Gazouli, A. Lyberopoulou, G. Polymeneas, and D. Voros, "Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance, "Molecular Carcinogenesis, vol. 52, no. 4, pp. 297-303, 2013.
120. M. D. Giraldez, J. J. Lozano, G. Ramrez et al., "Circulating MicroRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study, " Clinical Gastroenterology and Hepatology, vol. 11, no. 6, pp. 681. e3-688. e3, 2013.
121. Q. Wang, Z. Huang, S. Ni et al., "Plasma miR-601 and miR-are novel biomarkers for the early detection of colorectal cancer, " PLoS ONE, vol. 7, no. 9, Article ID e44398, 2012.
122. H. Cheng, L. Zhang, D. E. Cogdell et al., "Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis, " PLoS ONE, vol. 6, no. 3, Article ID e17745, 2011.
123. G. A. Ganepola, J. R. Rutledge Suman, P. Suman, A. Yiengpruksawan, and D. H. Chang, "Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer, " World Journal of Gastrointestinal Oncology, vol. 6, no. 1, pp. 22-33, 2014.
124. N. A. Schultz, C. Dehlendorff, B. V. Jensen et al., "MicroRNA biomarkers in whole blood for detection of pancreatic cancer, " JAMA-Journal of the American Medical Association, vol. 311, no. 4, pp. 392-404, 2014.
125. G. Zhao, J.-G. Zhang, Y. Shi et al., "MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3, " PLoS ONE, vol. 8, no. 9, Article ID e73803, 2013.
126. W. A. Mardin and S. T. Mees, "MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?" Annals of Surgical Oncology, vol. 16, no. 11, pp. 3183-3189, 2009.
127. Z.-H. Chen, G.-L. Zhang, H.-R. Li et al., "A panel of five circulating microRNAs as potential biomarkers for prostate cancer, " Prostate, vol. 72, no. 13, pp. 1443-1452, 2012.
128. R. Mahn, L. C. Heukamp, S. Rogenhofer, A. von Ruecker, S. C. Muller, and J. Ellinger, "Circulating microRNAs (miRNA) in serum of patients with prostate cancer, " Urology, vol. 77, no. 5, pp. 1265. e9-1265. e16, 2011.
129. J. Shen, G. W. Hruby, J. M. McKiernan et al., "Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer, " Prostate, vol. 72, no. 13, pp. 1469-1477, 2012.
130. H.-L. Zhang, L.-F. Yang, Y. Zhu et al., "Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy, " Prostate, vol. 71, no. 3, pp. 326-331, 2011.
131. K. E. Resnick, H. Alder, J. P. Hagan, D. L. Richardson, C. M. Croce, and D. E. Cohn, "The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform, " Gynecologic Oncology, vol. 112, no. 1, pp. 55-59, 2009.
132. P. P. Shah, L. E. Hutchinson, and S. S. Kakar, "Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer, " Journal of Ovarian Research, vol. 2, no. 1, article 11, 2009.
133. M. S. Zaman, D. M. Maher, S. Khan, M. Jaggi, and S. C. Chauhan, "Current status and implications of microRNAs in ovarian cancer diagnosis and therapy, " Journal of Ovarian Research, vol. 5, no. 1, article 44, 2012.
134. C. W. S. Kan, M. A. Hahn, G. B. Gard et al., "Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer, " BMC Cancer, vol. 12, article 627, 2012.
135. S. Qiu, S. Lin, D. Hu, Y. Feng, Y. Tan, and Y. Peng, "Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients, " Journal of Translational Medicine, vol. 11, no. 1, article 10, 2013.
136. A. Conti, M. Aguennouz, D. La Torre et al., "miR-21 and 221 upregulation and miR-181b downregulation in human grade IIIV astrocytic tumors, " Journal of Neuro-Oncology, vol. 93, no. 3, pp. 325-332, 2009.
137. H. F. Tu, S. C. Lin, and K. W. Chang, "MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance, " Current Opinion in Otolaryngology and Head and Neck Surgery, vol. 21, no. 2, pp. 104-111, 2013.
138. A. B. Y. Hui, M. Lenarduzzi, T. Krushel et al., "Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas, " Clinical Cancer Research, vol. 16, no. 4, pp. 1129-1139, 2010.
139. A. B. Hui, W. Shi, P. C. Boutros et al., "Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues, " Laboratory Investigation, vol. 89, no. 5, pp. 597-606, 2009.
140. L. F. Sempere, M. Christensen, A. Silahtaroglu et al., "Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer, " Cancer Research, vol. 67, no. 24, pp. 11612-11620, 2007.
141. Y.-M. Lee, J.-Y. Lee, C.-C. Ho et al., "miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells, " Breast Cancer Research, vol. 13, no. 6, article R116, 2011.
142. R. Aharonov, D. Lebanony, H. Benjamin et al., "Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma, " Journal of Clinical Oncology, vol. 27, no. 12, pp. 2030-2037, 2009.
143. F. Fornari, M. Milazzo, P. Chieco et al., "In hepatocellular carcinomamiR-519d is up-regulated by p53 andDNAhypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2, " Journal of Pathology, vol. 227, no. 3, pp. 275-285, 2012.
144. M. Rong, R. He, Y. Dang, and G. Chen, "Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues, " Upsala Journal of Medical Sciences, vol. 119, no. 1, pp. 19-24, 2014.
145. Q. Zhi, J. Zhu, X. Guo et al., "Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage, " Biomedicine and Pharmacotherapy, vol. 67, no. 5, pp. 393-398, 2013.
146. M. Koelz, J. Lense, F. Wrba, M. Scheffler, H. P. Dienes, and M. Odenthal, "Down-regulation of miR-221 and miR-222 correlateswith pronouncedKit expression in gastrointestinal stromal tumors, " International Journal of Oncology, vol. 38, no. 2, pp. 503-511, 2011.
147. M. Bloomston, W. L. Frankel, F. Petrocca et al., "MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis, " Journal of the American Medical Association, vol. 297, no. 17, pp. 1901-1908, 2007.
148. T. Greither, L. F. Grochola, A. Udelnow, C. Lautenschlager, P. Wurl, and H. Taubert, "Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival, " International Journal of Cancer, vol. 126, no. 1, pp. 73-80, 2010.
149. J. Yu, K. Ohuchida, K. Mizumoto et al., "MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation, "Molecular Cancer, vol. 9, article 169, 2010.
150. X. Hu, J. K. Schwarz, J. S. Lewis Jr. et al., "A microRNA expression signature for cervical cancer prognosis, " Cancer Research, vol. 70, no. 4, pp. 1441-1448, 2010.
151. A. Laios, S. O'Toole, R. Flavin et al., "Potential role of miR-9 and miR-223 in recurrent ovarian cancer, " Molecular Cancer, vol. 7, article 35, 2008.
152. A. Masamune, E. Nakano, S. Hamada, T. Takikawa, N. Yoshida, and T. Shimosegawa, "Alteration of the microRNA expression profile during the activation of pancreatic stellate cells, " Scandinavian Journal of Gastroenterology, vol. 49, no. 3, pp. 323-331, 2014.
153. S. Saini, S. Majid, S. Yamamura et al., "Regulatory role of mir-in prostate cancer progression and metastasis, " Clinical Cancer Research, vol. 17, no. 16, pp. 5287-5298, 2011.
154. C. W. Wu, S. C. Ng, Y. Dong et al., "Identification of microrna-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma, " Clinical Cancer Research, vol. 20, no. 11, pp. 2994-3002, 2014.
155. F. L. Yong, C. W. Law, and C. W. Wang, "Potentiality of a triple microRNA classifier: MiR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer, " BMC Cancer, vol. 13, article 280, 2013.
156. U. Segersten, Y. Spector, Y. Goren, S. Tabak, and P.-U. Malmstr om, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer, " Urologic Oncology: Seminars and Original Investigations, vol. 32, no. 5, pp. 613-618, 2014.
157. T. Ichimi, H. Enokida, Y. Okuno et al., "Identification of novel microRNA targets based on microRNA signatures in bladder cancer, " International Journal of Cancer, vol. 125, no. 2, pp. 345-352, 2009.
158. C. Yang, C. Wang, X. Chen et al., "Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas, " International Journal of Cancer, vol. 132, no. 1, pp. 116-127, 2013.
159. C. Eichelser, D. Flesch-Janys, J. Chang-Claude, K. Pantel, andH. Schwarzenbach, "Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-in human breast cancer development and progression., " Clinical chemistry, vol. 59, no. 10, pp. 1489-1496, 2013.
160. Q. Wu, C. Wang, Z. Lu, L. Guo, and Q. Ge, "Analysis of serum genome-wide microRNAs for breast cancer detection, " Clinica Chimica Acta, vol. 413, no. 13-14, pp. 1058-1065, 2012.
161. G. Rabinowits, C. Gercel-Taylor, J. M. Day, D. D. Taylor, and G. H. Kloecker, "Exosomal microRNA: a diagnostic marker for lung cancer, " Clinical Lung Cancer, vol. 10, no. 1, pp. 42-46, 2009.
162. P. Qi, S.-Q. Cheng, H. Wang, N. Li, Y.-F. Chen, and C.-F. Gao, "Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection, " PLoS ONE, vol. 6, no. 12, Article IDe28486, 2011.
163. Y. Yamamoto, N. Kosaka, M. Tanaka et al., "MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma, " Biomarkers, vol. 14, no. 7, pp. 529-538, 2009.
164. J. Xu, C. Wu, X. Che et al., "Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis, " Molecular Carcinogenesis, vol. 50, no. 2, pp. 136-142, 2011.
165. J. Qi, J. Wang, H. Katayama, S. Sen, and S. M. Liu, "Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma, " Neoplasma, vol. 60, no. 2, pp. 135-142, 2013.
166. K. Z. Qu, K. Zhang, H. R. Li, N. H. Afdhal, and M. Albitar, "CirculatingMicroRNAs as biomarkers for hepatocellular carcinoma, " Journal of Clinical Gastroenterology, vol. 45, no. 4, pp. 355-360, 2011.
167. M.-Y. Song, K.-F. Pan, H.-J. Su et al., "Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer, " PLoSONE, vol. 7, no. 3, Article IDe33608, 2012.
168. R. Liu, C. Zhang, Z. Hu et al., "A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis, " European Journal of Cancer, vol. 47, no. 5, pp. 784-791, 2011.
169. B.-S. Li, Y.-L. Zhao, G. Guo et al., "Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection, " PLoS ONE, vol. 7, no. 7, Article ID e41629, 2012.
170. H. Konishi, D. Ichikawa, S. Komatsu et al., "Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma, " British Journal of Cancer, vol. 106, no. 4, pp. 740-747, 2012.
171. J. J. LaConti, N. Shivapurkar, A. Preet et al., "Tissue and serum microRNAs in the Kras12 transgenic animal model and in patients with pancreatic cancer, " PLoS ONE, vol. 6, no. 6, Article ID e20687, 2011.
172. S. Yabushita, K. Fukamachi, H. Tanaka et al., "Circulating micrornas in serum of human k-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas, " Pancreas, vol. 41, no. 7, pp. 1013-1018, 2012.
173. J. Wang, J. Chen, P. Chang et al., "MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel bloodbased biomarkers of disease, " Cancer Prevention Research, vol. 2, no. 9, pp. 807-813, 2009.
174. R. Que, G. Ding, J. Chen, and L. Cao, "Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma, " World Journal of Surgical Oncology, vol. 11, article no. 219, 2013.
175. L.-G. Wang and J. Gu, "Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis, " Cancer Epidemiology, vol. 36, no. 1, pp. e61-e67, 2012.
176. Z. Huang, D. Huang, S. Ni, Z. Peng, W. Sheng, and X. Du, "Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer, " International Journal of Cancer, vol. 127, no. 1, pp. 118-126, 2010.
177. J. B. Kjersem, T. Ikdahl, O. C. Lingjaerde, T. Guren, K. M. Tveit, and E. H. Kure, "Plasma microRNAs predicting clinical outcome inmetastatic colorectal cancer patients receiving firstline oxaliplatin-based treatment, " Molecular Oncology, vol. 8, no. 1, pp. 59-67, 2014.
178. X.-X. Pu, G.-L. Huang, H.-Q. Guo et al., "Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression, " Journal of Gastroenterology and Hepatology, vol. 25, no. 10, pp. 1674-1680, 2010.
179. A. E. Frampton, J. Krell, T. M. H. Gall, L. Castellano, J. Stebbing, and L. R. Jiao, "MIR-15b and MIR-17 are tumorderived plasma micrornas dysregulated in colorectal neoplasia, " Annals of Surgery, 2014.
180. H. Zheng, L. Zhang, Y. Zhao et al., "Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer, " PLoS ONE, vol. 8, no. 11, Article ID e77853, 2013.
181. A. M. Westermann, D. Schmidt, S. Holdenrieder et al., "Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study, " Anticancer research, vol. 34, no. 2, pp. 665-669, 2014.
182. F. Moltzahn, A. B. Olshen, L. Baehner et al., "Microfluidicbased multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients, " Cancer Research, vol. 71, no. 2, pp. 550-560, 2011.
183. L. Dyrskjøt, M. S. Ostenfeld, J. B. Bramsen et al., "Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro, " Cancer Research, vol. 69, no. 11, pp. 4851-4860, 2009.
184. A. Tolle, M. Jung, S. Rabenhorst, E. Kilic, K. Jung, and S. Weikert, "Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer, " Oncology Reports, vol. 30, no. 4, pp. 1949-1956, 2013.
185. Z. C. Zhang, Y. Huang, X. J. Wang, M. Wang, and L. L. Ma, "Expression of circulating microRNAs in patients with bladder urothelial carcinoma, " Journal of Peking University Health Sciences, vol. 45, no. 4, pp. 532-536, 2013.
186. G. Wang, E. S.-Y. Chan, B. C.-H. Kwan et al., "Expression of microRNAs in the urine of patients with bladder cancer, " Clinical Genitourinary Cancer, vol. 10, no. 2, pp. 106-113, 2012.
187. C. Fang, D.-X. Zhu, H.-J. Dong et al., "Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma, " Annals of Hematology, vol. 91, no. 4, pp. 553-559, 2012.
188. F. Zhi, X. Cao, X. Xie et al., "Identification of circulating MicroRNAs as potential biomarkers for detecting acutemyeloid leukemia, " PLoS ONE, vol. 8, no. 2, Article ID e56718, 2013.
189. B. Stamatopoulos, N. Meuleman, B. Haibe-Kains et al., "microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification, " Blood, vol. 113, no. 21, pp. 5237-5245, 2009.